R723, a selective JAK2 inhibitor, effectively treats JAK2V617F-induced murine myeloproliferative neoplasm

Area of Science:

• Hematology
• Oncology
• Pharmacology

Background:

• Activating mutations in Janus kinase 2 (JAK2), such as JAK2V617F, are central to the pathogenesis of myeloproliferative neoplasms (MPNs).
• Targeting the aberrant JAK2 signaling pathway is a key therapeutic strategy for MPNs.

Purpose of the Study:

• To evaluate the preclinical efficacy and safety of R723, a novel small molecule inhibitor of JAK2.
• To assess the potential of R723 as a treatment for JAK2V617F-positive MPNs.

Main Methods:

• In vitro assessment of R723's inhibitory activity against JAK family kinases.
• Evaluation of R723's effects on primary hematopoietic cells with JAK2V617F.
• Assessment of R723 in mouse models of anemia, JAK2V617F-driven leukemia, and primary myelofibrosis.

Main Results:

• R723 selectively inhibited JAK2 activity in vitro with minimal effects on JAK1, JAK3, and TYK2.
• R723 suppressed cytokine-independent cell growth and STAT5 activation in JAK2V617F-expressing cells.
• In vivo, R723 improved survival, reduced tumor burden, and ameliorated MPN-related phenotypes in relevant mouse models, demonstrating a favorable safety profile.

Conclusions:

• R723 is a potent and selective JAK2 inhibitor with significant preclinical efficacy in MPN models.
• R723 demonstrates a favorable safety profile and warrants further investigation as a potential therapeutic agent for JAK2V617F-positive MPNs.